Clinical Trial Details


Back to Clinical Trials Database

Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction, metastatic or not amenable to curative surgery according to HER2 and EGFR status: a randomized phase II trial.

Study documentation

Trial Status All trial activities ended
Dates Date of activation: 09-Dec-2010
Date Step1 close: 09-Aug-2013
Data management at EORTC Yes
Design Phase 2
Randomized blind
Targeted Sample size EORTC Groups: 192 - All Groups: 192
Treatment Fluorouracil, Capecitabine, Cisplatin, Epirubicin, Lapatinib
Study Staff
Type of cancer
Participating groups EORTC Gastrointestinal Tract Cancer Group
Protocol summary
NCT number NCT01123473
EudraCT 2009-011580-36